SAR439859 plus palbociclib as first line therapy for patients with ER (+) HER2(-) advanced breast cancer (AMEERA-5) | NYU Langone Health

Go Back to All Clinical Trials

SAR439859 plus palbociclib as first line therapy for patients with ER (+) HER2(-) advanced breast cancer (AMEERA-5)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Er (+) Her2 (-) Breast Cancer
Age: Between 18 years - 100 years
Gender: Male or Female

Other Inclusion Criteria:

1) Adult participants with loco-regional recurrent or metastatic disease not amenable to curative treatment. 2) Confirmed diagnosis of ER+/HER2- breast cancer. 3) No prior systemic treatment for loco-regional recurrent or metastatic disease. 4) Measurable or non-measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1.

You may not be eligible for this study if the following are true:

1) Patients previously treated for advanced breast cancer with hormonal therapy and cell cycle inhibitors. 2) Participants with known brain metastases that are untreated, symptomatic or require therapy to control symptoms. 3) Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of SAR439859 and/or palbociclib.